Literature DB >> 20482375

Congenital hyperinsulinism in Brazilian neonates: a study of histology, KATP channel genes, and proliferation of β cells.

Silvana M Lovisolo1, Berenice B Mendonça, Emilia M Pinto, Thais Della Manna, Paulo Hilário N Saldiva, Maria Cláudia N Zerbini.   

Abstract

Congenital hyperinsulinism (CHI) is a rare pancreatic β-cell disease of neonates, characterized by inappropriate insulin secretion with severe persistent hypoglycemia, with regard to which many questions remain to be answered, despite the important acquisition of its molecular mechanisms in the last decade. The aim of this study was to examine pancreatic histology, β-cell proliferation (immunohistochemistry with double staining for Ki-67/insulin), and β-cell adenosine triphosphate-sensitive potassium channels genes from 11 Brazilian patients with severe medically unresponsive CHI who underwent pancreatectomy. Pancreatic histology and β-cell proliferation in CHI patients were compared to pancreatic samples from 19 age-matched controls. Ten cases were classified as diffuse form (D-CHI) and 1 as focal form (F-CHI). β-cell nucleomegaly and abundant cytoplasm were absent in controls and were observed only in D-CHI patients. The Ki-67 labeling index (Ki-67-LI) was used to differentiate the adenomatous areas of the F-CHI case (10.15%) from the "loose cluster of islets" found in 2 D-CHI samples (2.29% and 2.43%) and 1 control (1.54%) sample. The Ki-67-LI was higher in the F-CHI adenomatous areas, but D-CHI patients also had significantly greater Ki-67-LI (mean value  =  2.41%) than age-matched controls (mean value  =  1.87%) (P  =  0.009). In this 1st genetic study of CHI patients in Brazil, no mutations or new polymorphisms were found in the 33-37 exons of the ABCC8 gene (SUR1) or in the entire exon of the KCNJ11 gene (Kir 6.2) in 4 of 4 patients evaluated. On the other hand, enhanced β-cell proliferation seems to be a constant feature in CHI patients, both in diffuse and focal forms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482375     DOI: 10.2350/08-12-0578.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  5 in total

1.  Persistent hyperinsulinemic hypoglycemia of infancy: constitutive activation of the mTOR pathway with associated exocrine-islet transdifferentiation and therapeutic implications.

Authors:  Sanda Alexandrescu; Nina Tatevian; Oluyinka Olutoye; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-08-08

2.  SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism.

Authors:  Väinö Lithovius; Jonna Saarimäki-Vire; Diego Balboa; Hazem Ibrahim; Hossam Montaser; Tom Barsby; Timo Otonkoski
Journal:  Diabetologia       Date:  2021-01-06       Impact factor: 10.122

3.  Altered Phenotype of β-Cells and Other Pancreatic Cell Lineages in Patients With Diffuse Congenital Hyperinsulinism in Infancy Caused by Mutations in the ATP-Sensitive K-Channel.

Authors:  Rachel J Salisbury; Bing Han; Rachel E Jennings; Andrew A Berry; Adam Stevens; Zainab Mohamed; Sarah A Sugden; Ronald De Krijger; Sarah E Cross; Paul P V Johnson; Melanie Newbould; Karen E Cosgrove; Karen Piper Hanley; Indraneel Banerjee; Mark J Dunne; Neil A Hanley
Journal:  Diabetes       Date:  2015-04-30       Impact factor: 9.461

4.  Atypical Forms of Congenital Hyperinsulinism in Infancy Are Associated With Mosaic Patterns of Immature Islet Cells.

Authors:  Bing Han; Zainab Mohamed; Maria Salomon Estebanez; Ross J Craigie; Melanie Newbould; Edmund Cheesman; Raja Padidela; Mars Skae; Matthew Johnson; Sarah Flanagan; Sian Ellard; Karen E Cosgrove; Indraneel Banerjee; Mark J Dunne
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

5.  Enhanced Islet Cell Nucleomegaly Defines Diffuse Congenital Hyperinsulinism in Infancy but Not Other Forms of the Disease.

Authors:  Bing Han; Melanie Newbould; Gauri Batra; Edmund Cheesman; Ross J Craigie; Zainab Mohamed; Lindsey Rigby; Raja Padidela; Mars Skae; Aleksandr Mironov; Tobias Starborg; Karl E Kadler; Karen E Cosgrove; Indraneel Banerjee; Mark J Dunne
Journal:  Am J Clin Pathol       Date:  2016-06       Impact factor: 2.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.